SAINT LAURENT, Quebec, Nov. 9, 2022 (GLOBE NEWSWIRE) — IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”), a leader in pharmaceutical films, today announced the launch of Companion Animal Entered into a feasibility study and development agreement (the “Agreement”) with a privately held animal health company focused on the development of a VetaFilm™-based oral film formulation containing CBD for use in:
Under the agreement, IntelGenx will provide a prototype of its CBD-infused VetaFilm™ product for clinical research. Based on successful feasibility, IntelGenx will enter into commercial contract negotiations. IntelGenx thereby obtains exclusive rights to further develop, manufacture and supply the developed products.
Dr. Horst G. Zerbe, CEO of IntelGenx, said: “We are excited to make our CBD-infused VetaFilm™ products available to the global CBD pet market. It is expected to reach the dollar.”
About Intel Genx
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
Superior film technology from IntelGenx including VersaFilm®DisinteQ™VetaFilm™ and transdermal VevaDerm™, enabling next-generation medicines that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians across many therapeutic conditions.
IntelGenx’s highly skilled team provides pharmaceutical partners with comprehensive pharmaceutical services including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility provides full service by offering lab-scale to pilot-scale and commercial-scale production. For more information, please visit www.intelgenx.com.
Forward-Looking Information and Statements
This document may contain forward-looking information regarding IntelGenx’s performance and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements regarding IntelGenx’s plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances. Expressions such as “intend”, “plan”, “believe”, “seek”, “estimate”, “could”, “would”. All forward-looking statements are qualified in full and expressly by this cautionary statement. These forward-looking statements involve a number of risks and uncertainties that could cause IntelGenx’s actual results to differ materially from those expressed or implied by these forward-looking statements. Factors that may cause or contribute to such differences are filed with the U.S. Securities and Exchange Commission and with the Canadian securities regulators at www.sedar.com. . IntelGenx does not undertake any obligation to update such forward-looking statements.
sauce: Intel Genx Technologies Corp.
For IntelGenx:
Stephen Kilmer
Investor information
(647) 872-4849
stephen@kilmerlucas.com
or
Andre Godin, CPA, California
President and CFO
intelgenx
(514) 331-7440 ext. 203
andre@intelgenx.com
